PRINCETON, N.J. & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company was granted conditional approval status for its ROS1 lung cancer biomarker by Fluorescence in situ Hybridization (FISH) assay from the New York State Department of Health (“NYSDOH”) under the Company’s Molecular Oncology permit. New York is the only U.S. state that requires an independent regulatory review process for laboratory-developed tests. With this conditional approval, Rosetta Genomics’ ROS1 by FISH assay is now available in all 50 states. In making the assay available pending final approval, the NYSDOH requires the Company to provide any additional information they request within 60 business days.
Help employers find you! Check out all the jobs and post your resume.
